<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287896</url>
  </required_header>
  <id_info>
    <org_study_id>ADNC-1301</org_study_id>
    <secondary_id>2013-000269-35</secondary_id>
    <nct_id>NCT02287896</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of Roledumab, in RhD-negative Pregnant Women Carrying an RhD-positive Foetus</brief_title>
  <official_title>Pharmacokinetics and Safety of Roledumab, a Fully Human Recombinant Monoclonal Anti-RhD Antibody, in RhD-negative Pregnant Woman Carrying an RhD-positive Foetus: a Phase IIb, Multicenter, Open-label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoire français de Fractionnement et de Biotechnologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the pharmacokinetic profile of Roledumab 300μg IM / IV in
      RhDnegative pregnant women carrying an RhD-positive foetus.

      And to assess the safety of Roledumab in RhD-negative pregnant women and in RhD-positive
      foetus and newborns.

      In addition the efficacy of Roledumab 300μg IM and IV to prevent RhD alloimmunisation in
      RhDnegative pregnant women carrying an RhD-positive foetus and the immunogenicity of
      Roledumab will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">September 13, 2017</completion_date>
  <primary_completion_date type="Actual">September 13, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Profile of Pharmacokinetics of Roledumab (IM) in RhD-negative pregnant women carrying an RhD-positive foetus.</measure>
    <time_frame>inclusion, Day 3, Day 6, Day 10, Day 30, Day 60, before delivery, Day 4 and Day 10, Week 6 after delivery injection</time_frame>
    <description>C max, Area under the surve, T max, Elimination rate constant, Terminal half-live, Clearance, Volume of distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Profile of Pharmacokinetics of Roledumab (IV) in RhD-negative pregnant women carrying an RhD-positive foetus.</measure>
    <time_frame>inclusion, Hour 1, Day 2, Day 3, Day 5-6, Day 30, Day 60, before delivery, Day 4 and Day 10, Week 6 after delivery injection</time_frame>
    <description>C max, Area under the surve, T max, Elimination rate constant, Terminal half-live, Clearance, Volume of distribution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of mother and foetus/newborn, incidence of AEs :changes in physical examination findings, and vital sign measurements, clinical laboratory tests and Doppler ultrasound.</measure>
    <time_frame>from screening visit to 6 months after delivery</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Roledumab first/breast milk concentration</measure>
    <time_frame>Day 4 and Day 10 after delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Roledumab maternal serum concentration ratio</measure>
    <time_frame>Day 4 and Day 10 after delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Roledumab cord blood concentration</measure>
    <time_frame>At delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Roledumab cord blood maternal serum concentration ratio cord blood concentration/maternal serum concentration ratio will be also collected</measure>
    <time_frame>At delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>RhD-alloimmunisation rate</measure>
    <time_frame>at 6 months and up to 12 months after delivery if applicable</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity of Roledumab</measure>
    <time_frame>inclusion, Day 10, Day 30 before delivery, before postpartum administration, Day 10, Week 6 and Month 6 after postpartum injection</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Rh Disease</condition>
  <arm_group>
    <arm_group_label>Roledumab Open-label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Planned antenatal prophylaxis: A single dose of 300 µg IM/IV of Roledumab at 28 or 29 weeks of gestation.
- Antenatal prophylaxis following sensitising events: One or more dose(s) of 300μg IM/IV anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.
- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.
The postnatal dose must still be given even when antenatal prophylaxis has been administered.
Before Roledumab 300μg IM/IV postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal haemorrhage (FMH).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ROLEDUMAB</intervention_name>
    <description>See Arm description</description>
    <arm_group_label>Roledumab Open-label</arm_group_label>
    <other_name>ADNC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent form provided by the subject prior to proceeding
             with any study-related procedure,

          -  At least 18 years old,

          -  Pregnancy between 12 and 27 weeks gestational age as confirmed by early ultrasound,

          -  Pregnant RhD-negative woman carrying a RhD-positive foetus confirmed by a non-invasive
             foetal RhD genotyping test

          -  Negative serology: hepatitis B and C, HIV (1 and 2), except for positive results due
             to vaccinations,

          -  Covered by healthcare insurance in accordance with local requirements.

        Exclusion Criteria:

          -  RhD allo-immunised subject,

          -  Positive for ADA Test,

          -  Multiple foetuses,

          -  Occurrence of a documented potential sensitizing event in this pregnancy before the
             antenatal IMP administration,

          -  Prior administration of anti-RhD immunoglobulin during the current pregnancy,

          -  Known clinically relevant maternal or foetal abnormality (e.g., as determined by
             ultrasound or genetic testing), such as placenta previa,

          -  History of anaphylactic or severe systemic reaction to immunoglobulin of any origin,

          -  Current diagnosis of an immune disease which by itself or its treatment could impair
             the safety and/or efficacy evaluation of Roledumab in this study. These diseases are:
             All immune deficiencies, particularly those requiring IV-Ig supplementation or other
             systemic treatment / connective tissue and autoimmune diseases (e.g., systemic lupus
             erythematosus, antiphospholipid syndrome, Sjögren's syndrome, rheumatoid arthritis,
             ankylosing spondylarthritis) requiring systemic immunosuppressive treatment / allergic
             and inflammatory diseases requiring systemic immunosuppressive treatment.

          -  Clinically significant medical history contraindicating the participation in the study
             according to the judgment of the Investigator or Sponsor,

          -  Clinically significant laboratory (haematology, blood chemistry, or urinalysis)
             parameters,

          -  Transfusion of RhD-positive blood or blood derived products within the 6 months prior
             to enrolment,

          -  Anticipated poor compliance with the study procedures,

          -  Subject within exclusion period further to her participation in a clinical study,

          -  For the IM arm only, subject with coagulation disorders contraindicating intramuscular
             injection (patient will still be considered for the IV arm)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno CARBONNE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Princesse Grace</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vassilis TSATSARIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maternité Port-Royal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre, CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternité de la Croix-Rousse, CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternité Port-Royal, Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Poissy-Saint-Germain</name>
      <address>
        <city>Poissy</city>
        <zip>78303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut mère et enfant Alix de champagne, CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pôle de gynécologie Obstétrique et Médecine de la Reproduction</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RhD-negative pregnant woman</keyword>
  <keyword>anti-RhD antibody</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

